Clinical outcome and prognostic factors in dogs with B-cell chronic lymphocytic leukemia: A retrospective study

Emily D. Rout1 | Julia D. Labadie1 | Janna A. Yoshimoto1 | Paul R. Avery1 | Kaitlin M. Curran2 | Anne C. Avery1

1Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado
2Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon

Correspondence
Emily D. Rout, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 200 West Lake Street, Fort Collins, CO 80523.
Email: emily.rout@colostate.edu

Funding Information
Morris Animal Foundation, Grant/Award Number: D18CA-413

Abstract

Background: B-cell chronic lymphocytic leukemia (BCLL) in dogs generally is considered an indolent disease, but previous studies indicate a wide range in survival times.

Objectives: We hypothesized that BCLL has a heterogeneous clinical course, similar to chronic lymphocytic leukemia in humans. We aimed to assess presentation and outcome in dogs with BCLL and evaluate the prognostic relevance of clinical and flow cytometric factors.

Animals: One hundred and twenty-one dogs with BCLL diagnosed by flow cytometry. Three breed groups were represented: small breed dogs (n = 55) because of increased risk of BCLL; Boxers (n = 33) because of preferential use of unmutated immunoglobulin genes; and other breeds (n = 33).

Methods: Retrospective study reviewing signalment, clinicopathologic data, physical examination findings, treatment, and survival of dogs with BCLL. Cellular proliferation, determined by the percentage of Ki67-expressing CD21+B-cells by flow cytometry, was measured in 39 of 121 cases. Clinical and laboratory variables were evaluated for association with survival.

Results: The median survival time (MST) for all cases was 300 days (range, 1-1644 days). Boxers had significantly shorter survival (MST, 178 days) than non-Boxers (MST, 423 days; P < .0001), and no significant survival difference was found between small breeds and other non-Boxer breeds. Cases with high Ki67 (>40% Ki67-expressing B-cells) had significantly shorter survival (MST, 173 days) than did cases with <40% Ki67 (MST undetermined; P = .03), regardless of breed. Cases with a high lymphocyte count (>60 000 lymphocytes/μL) or clinical signs at presentation had significantly shorter survival.

Conclusions and Clinical Importance: B-cell chronic lymphocytic leukemia had a variable clinical course and Boxer dogs and cases with high Ki67 had more aggressive disease.
1 | INTRODUCTION

B-cell chronic lymphocytic leukemia (BCLL) is a malignancy of small-sized B-cells in the blood and bone marrow and a common form of leukemia in dogs. It represented 8% of all samples with suspicion of lymphoproliferative disease (of any site) in 1 study and 36% of CLL cases in dogs in another study. Diagnostic criteria for BCLL vary, generally requiring >5000 to 6000 lymphocytes/μL in the blood and identification of B-cell expansion by immunophenotyping. Some studies incorporate small mature cytomorphology or small cell size by flow cytometry as inclusion criteria, and some exclude cases with moderate-to-severe lymphadenopathy or splenomegaly. The disease generally affects older dogs (median age, 10-11.9 years). A previous study indicated that certain small dog breeds have increased risk of BCLL, and approximately half of cases have lymphadenopathy or splenomegaly.

In people, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a common B-cell neoplasm in the blood, bone marrow, lymph nodes, and spleen. A diagnosis of CLL requires >5000 B-cells/μL in the blood and SLL requires lymphadenopathy, splenomegaly, or both with <5000 B-cells/μL, but these entities are considered different manifestations of the same disease. In humans, CLL/SLL has a highly variable clinical course and genetic and clinical variables are used to assess prognosis. In dogs, BCLL generally is considered an indolent disease, but studies indicate a wide range in survival times.

The goal of our study was to assess survival and prognostic factors in a larger number of dogs with BCLL, defined by an expansion of small-sized B-cells in the blood by flow cytometry. We did not exclude cases with lymphadenopathy, splenomegaly or cytopenias, because doing so may exclude true BCLL cases. Although it is possible some cases in our study had a different small B-cell neoplasm, we wanted to include all cases with small cell B-cell lymphocytosis in the blood, because it is unknown whether cases with tissue infiltration are a different manifestation of BCLL vs an entirely different neoplasm. We evaluated Ki67 expression for association with survival. It is a marker of proliferation with prognostic value in high-grade B-cell lymphomas of dogs when measured by flow cytometry. In humans with CLL, high Ki67 expression is associated with poorer outcome, whether measured in neoplastic peripheral lymphocytes, lymph node proliferation centers, or plasma. Additionally, Boxers with BCLL preferentially rearrange unmutated immunoglobulin heavy variable region genes, which is a poor prognostic indicator in humans with CLL, and our study aimed to examine breed-related differences in presentation and outcome. We hypothesized that BCLL in dogs has a variable clinical course similar to CLL in humans and that Boxers and dogs with high Ki67 expression would have more aggressive disease.

2 | MATERIALS AND METHODS

2.1 | Study population

The Colorado State University Clinical Hematopathology laboratory database was queried for BCLL cases in dogs with blood submitted for flow cytometry between October 2010 and October 2018. Inclusion criteria included: (a) >5000 lymphocytes/μL on CBC, (b) >60% of lymphocytes expressed CD21, (c) no cells expressed CD34, (d) B-cells were small-sized, defined by B-cell:neutrophil median forward scatter ≤0.60, Cases initially were selected randomly to represent the general BCLL population. Additional Boxer cases were sought because Boxers with BCLL preferentially rearrange unmutated immunoglobulin heavy variable region genes, which is associated with poor prognosis in humans with CLL. English bulldogs were excluded because this breed develops a condition of non-neoplastic, polyclonal B-cell expansion. We rarely have identified this polyclonal B-cell syndrome in other breeds, but no cases in this BCLL study had the characteristics of that syndrome.

For controls to evaluate CD21, CD25, and class II major histocompatibility complex (MHC) expression on normal B-cells, routine flow cytometry was performed on blood from 30 healthy dogs with normal lymphocyte subsets by flow cytometry and polyclonal gene rearrangements by PCR for antigen receptor rearrangements (PARR). Between June 2017 and August 2019, we performed Ki67 staining by flow cytometry (Appendix S1) on randomly selected BCLL cases, nodal B-cell lymphoma cases, and controls. Nodal B-cell lymphoma cases were lymph node samples with a homogeneous expansion of CD21+ B-cells with a median forward scatter >500 by flow cytometry. Previously, B-cell lymphoma cases meeting these criteria were predominantly diffuse large B-cell lymphoma. For size comparison, canine blood neutrophils had a mean forward scatter of 620 (SD, 61). Additionally, Ki67 staining was performed on 7 lymph node aspirates and 5 blood samples from 12 control dogs with no evidence of lymphoproliferative disease. All BCLL cases with Ki67 data obtained between September 2017 and October 2018 were contacted for medical records.

In total, 435 BCLL cases were contacted for the outcome study from 3 queries ([a] initial query of cases of any breed, [b] additional Boxer cases, and [c] BCLL cases of any breed with Ki67 data) and the 121 cases with available medical records were included in the study. Additionally, separate from the outcome study population, a population of additional BCLL cases, nodal B-cell lymphoma cases, and controls had Ki67 analysis performed.

2.2 | Clinical variables

Medical records were reviewed for signalment, physical examination and imaging findings, clinicopathologic data, clinical signs, treatment,
and survival data. Anemia was defined by a hematocrit below the laboratory’s reference interval. Thrombocytopenia was defined by a platelet count below the laboratory’s reference interval with no evidence of platelet clumping. Hyperglobulinemia was defined by the upper limit of the reference interval on available serum biochemistry panels. Visceral lymph node, spleen, and liver abnormalities, including enlargement or masses, were identified by palpation, ultrasound examination, or thoracic or abdominal radiography. Blood smear evaluations, cytology reports, and histology reports from board-certified pathologists were reviewed. Lymphocyte size was determined by a variety of methods across pathologists, including micrometer measurement, comparison to erythrocyte diameter, or comparison to neutrophil diameter of the lymphocyte nucleus only or the entire lymphocyte diameter.

2.3 | Flow cytometry

Flow cytometry was performed as previously described, using antibody panels in Table S1. All cases had a blood sample submitted and 12 cases also had lymph node aspirates submitted. Expression of CD21, class II MHC, and CD25 on B-cells was determined for all cases submitted after May 11, 2012 (details in Appendix S1).

2.4 | Clonality testing

The PARR assay was performed as previously described. A small proportion of cases (13%) had PARR requested at the time of flow cytometry. For remaining cases, PARR was performed retrospectively for all cases with sample material available.

2.5 | Statistical analysis

Clinical and clinicopathologic data were summarized. To evaluate breed-specific differences, we grouped cases into 3 broad breed groups: (a) small dog breeds with a documented increased risk of BCLL, (b) Boxer dogs, and (c) other breeds. Continuous variables were compared using Kruskal-Wallis or Mann-Whitney tests and categorical variables were compared using Chi-squared tests. Overall survival was calculated as days from the time of the flow cytometry diagnosis, because this date was available for all cases. Cases lost to follow-up or alive at the time of data collection were censored at the last contact date. Deaths were categorized as: (a) “BCLL related” or “possibly BCLL related” depending on the degree of suspicion, as indicated by the clinician, or if there was disease progression noted at the time of death or euthanasia; (b) “unrelated” when indicated by the clinician; or (c) “possibly unrelated” when the cause of death or euthanasia was not indicated by the clinician. BCLL disease was stable or in remission, and co-morbidity conditions existed. Treatments were categorized as: (a) no treatment, (b) corticosteroids only, (c) corticosteroids and chlorambucil, or (d) maximum tolerated dose (MTD) injectable or PO chemotherapy (including single-agent and multi-agent protocols).

Treatments were described based on the initial treatment plan, the total number of chemotherapy protocols used, and the most intensive protocol used throughout BCLL treatment. When possible, best response to treatment was retrospectively evaluated based on lymphocyte cell count, status of cytophenias on CBC, and status of clinical signs noted in the medical record. Responses were classified as follows: complete response (CR), no morphologically atypical cells, normal total lymphocyte count, and resolution of clinical signs; partial response (PR), >50% reduction in lymphocyte count, persistent clinical signs or both; stable disease (SD), <50% reduction in lymphocyte count/≤25% increase in lymphocyte count, with or without persistent clinical signs; and progressive disease (PD), >25% increase in circulating lymphocyte count, with or without worsening clinical signs.

For survival analysis, continuous risk factors were divided into groups above and below the median, except for lymphocyte count, which was grouped above and below 60 000 platelets/μL, because this cutoff was clinically relevant. Individuals with missing or unknown data were excluded from analysis. Blood smear lymphocyte morphology obtained from pathology report descriptions was categorized as: (a) intermediate-to-large-sized lymphocytes or (b) small-, small-to-intermediate-, or intermediate-sized lymphocytes. Associations between patient data and survival were assessed using Kaplan-Meier log-rank tests. For Ki67 analysis and survival analysis, the “other breeds” group was further divided into small breeds (body weight < 15 kg) and medium-large breeds (>15 kg), based on the American Kennel Club breed weight chart (AKC Material, URL: akc.org/expert-advice/nutrition/breed-weight-chart/). Statistical analysis was performed using GraphPad Prism version 7 or R version 3.5.2 and 2-sided P-values <.05 were considered significant.

3 | RESULTS

3.1 | Clinical presentation

Medical records were obtained for 121 BCLL cases, representing small breeds with increased BCLL risk (n = 55), Boxers (n = 33), and other breeds (n = 33). Signalment, clinicopathologic data, and physical examination findings at the time of diagnosis are summarized in Table 1. The median age of all cases was 10.4 years and 55% were male. The median lymphocyte count on CBC was 39 700 lymphocytes/μL. Forty-one percent of cases were anemic, with a median hematocrit of 31.5% (interquartile range [IQR], 26%-36%; range, 18%-39%). Of 34 anemic cases with a reticulocyte count performed, 50% had a regenerative anemia based on the laboratory’s reference interval (median, 119 000 reticulocytes/μL; IQR, 102 950-246 500/μL; range, 64 000-698 000/μL). Twenty-four percent of cases were thrombocytopenic with a median count of 113 000 platelets/μL (IQR, 91 500-156 000/μL; range, 30 000-198 000/μL).

Blood smear review by a clinical pathologist was available for 107 cases. Ninety-two percent of cases were described as having small-, small-to-intermediate-, or intermediate-sized lymphocytes, and of those, 93% were described as having mature chromatin patterns.
Nine cases had intermediate-to-large-sized lymphocytes cytologically, but these cases were included because the cells were small-sized based on flow cytometry. Other groups have highlighted differences in cell size between microscopy and flow cytometry and suggested flow cytometry is more objective for determining size.23-25 A few cases had descriptions of atypical chromatin patterns, including smooth, fine, or stippled. Moderate numbers of cases were described as having rare cells with a faint nucleolus, but 2 were described as having consistent nucleoli. Bone marrow cytology reports were available for 11 cases, and 3 were diagnosed with lymphocytic leukemia, 2 with lymphocytosis suspicious for CLL (40%-45% small lymphocytes), 3 with mild lymphocytosis (7%-16% small lymphocytes), 1 with few atypical lymphocytes consistent with possible lymphoid neoplasia, and 2 with normal lymphocyte number and morphology.

At diagnosis, 19% (n = 22) of cases were hyperglobulinemic. Serum protein electrophoresis was performed in 8 cases. Six had a monoclonal gammapathy and 2 had a biclonal gammapathy. Additional cases developed hyperglobulinemia after diagnosis and 25% had hyperglobulinemia during the course of disease.

Peripheral lymphadenopathy was detected in 53% of cases at diagnosis and 11 developed lymphadenopathy, resulting in 62% having peripheral lymphadenopathy. Lymph node cytology was evaluated in 37 cases and 43% were diagnosed as lymphoma (small-intermediate, n = 8; intermediate-large, n = 8), 22% as possible or probable lymphoma (small-intermediate), 24% as lymphoid hyperplasia or reactive, and 11% as within normal limits. By histology (n = 3), 1 case was diagnosed with low-grade small cell lymphoma, 1 with high-grade small cell lymphoma, and 1 with probable small cell lymphoma. Fifty-four percent of cases had splenic abnormalities at diagnosis, an additional 5 cases developed splenic abnormalities (splenic abnormalities in 58% of cases), and 2 had a history of previous splenectomy. Splenic cytology was evaluated in 17 cases and 29% were diagnosed as lymphoma (small-intermediate, n = 4; intermediate-large, n = 1), 41% as possible lymphoma, and 29% as lymphoid hyperplasia. By splenic histology (n = 3), 2 were diagnosed with low-to-intermediate-grade lymphoma of small-to-medium-sized lymphocytes and 1 was diagnosed with lymphoid hyperplasia.

### TABLE 1

| Signalment data, clinicopathologic data, physical exam findings, and treatment data for 121 BCLL patients in the outcome study |
|---------------------------------------------------------------|
| **Boxxers (n = 33)** | **Small breed (n = 55)** | **Other breeds (n = 33)** | **Non-Boxers** (n = 88) |
|-----------------|-----------------|-----------------|-----------------|
| **Age (years)** | 33 | 9.3 (8.3-10.7) | 55 | 10.9 (9.1-13.2) |
| **Male** | 33 | 15 (45) | 55 | 26 (47) |
| **Lymphocyte count, x10^7/μL** | 33 | 72.7 (32.9-138.1) | 55 | 32.0 (14.3-75.0) |
| **Anemia** | 33 | 15 (45) | 55 | 25 (45) |
| **Thrombocytopenia** | 33 | 12 (36) | 55 | 10 (18) |
| **Hyperglobulinemia** | 32 | 6 (19) | 52 | 12 (23) |
| **B-cell size ratio** | 33 | 0.52 (0.48-0.56) | 55 | 0.48 (0.44-0.51) |
| **CD25 expression (%)** | 30 | 72 (26-96) | 46 | 55 (21-81) |
| **Class II MHC expression (MFI)** | 30 | 127 (100-254) | 46 | 159 (102-220) |
| **CD21 expression (MFI)** | 30 | 46 (31-64) | 46 | 50 (35-70) |
| **Peripheral lymphadenopathy** | 32 | 21 (66) | 52 | 28 (54) |
| **Visceral lymphadenopathy** | 20 | 11 (55) | 31 | 12 (39) |
| **Splenic abnormalities** | 30 | 20 (67) | 41 | 24 (59) |
| **Hepatic abnormalities** | 30 | 9 (30) | 41 | 17 (41) |
| **Clinical signs at presentation** | 33 | 14 (42) | 54 | 20 (37) |
| **Maximum treatment** | 32 | 15 (47) | 18 (33) | 10 (30) | 28 (32) |
| **MTD chemotherapy** | 32 | 15 (47) | 18 (33) | 10 (30) | 28 (32) |
| **Steroid/chlorambucil** | 7 (22) | 19 (35) | 10 (30) | 29 (33) |
| **Steroids only** | 7 (22) | 7 (13) | 6 (18) | 13 (15) |
| **None** | 3 (9) | 11 (20) | 7 (21) | 18 (20) |

Abbreviations: IQR, interquartile range; MFI, median fluorescence intensity; MHC, major histocompatibility complex; MTD, maximum tolerated dose.

*Non-Boxer group: combined small breed and other non-Boxer cases.

*nb, number of cases with available data.

*cn, number of cases affected; %, percentage of cases affected among those cases with available data.

*The most intensive protocol pursued throughout BCLL treatment.
Forty-six percent of cases had thoracic or abdominal lymphadenopathy and 33% of cases had hepatic abnormalities. Ten cases (8%) were presumed to have rectal involvement and half of these (4% of all cases) had rectal prolapse. Lymphoma was diagnosed in rectal tissue in 3 cases by cytology (n = 1) or histology (n = 2). Two (1.6%) cases had multiple dermal or SC nodules diagnosed as lymphoma by cytology. Six (5%) cases had ocular changes presumed secondary to lymphoproliferative disease or hyperglobulinemia and hyperviscosity syndrome by the clinician. Five (4%) cases had neurologic signs suspected to be secondary to lymphoproliferative disease, but only 1 case had advanced imaging performed and that dog had multifocal disease throughout the spinal cord presumed secondary to progression of lymphoproliferative disease. Seven (6%) cases had pulmonary infiltrates on thoracic radiographs interpreted as possible neoplastic infiltrate by the radiologist.

Sixty-two percent of cases were asymptomatic at diagnosis and leukocytosis with or without lymphadenopathy was an incidental finding. Among the 38% of cases with clinical signs at presentation, lethargy (n = 21) and decreased appetite (n = 20) were most common, with weight loss (n = 12), vomiting (n = 9), diarrhea (n = 9), and labored breathing (n = 6) affecting smaller numbers.

3.2 | Flow cytometry

By flow cytometry, CD21+ B-cells accounted for 64% to 99% of lymphocytes in the blood in BCLL cases. The B-cell:neutrophil size ratio ranged from 0.37 to 0.60 (median, 0.50) in BCLL cases (n = 121), compared to 0.39 to 0.54 (median, 0.44) in healthy controls (n = 30). The percentage of B-cells expressing CD25 was significantly higher in BCLL cases (median, 64%; range, 0.6%-99%; n = 99) compared to controls (median, 11%; range, 2.0%-24%; P < .0001; Figure 1A). B-cell class II MHC expression was significantly lower in BCLL cases (median, 158; range, 12-1168; n = 99) compared to controls (median, 383; range, 256-511; P < .0001; Figure 1B). B-cell CD21 expression was not significantly different between BCLL cases (median, 48; range, 7-114; n = 99) and controls (median, 46; range, 30-57; P = .212; Figure 1C).

Flow cytometry was performed on lymph node aspirates in 12 BCLL cases. All lymph node samples had marked expansion of small-sized B-cells, consistent with a small B-cell neoplasm. The CD21+ B-cells accounted for 88% to 97% of all leukocytes and the median forward light scatter of B-cells was <500 (median, 407; range, 323-497) in all cases. B-cells in the lymph node were larger than the same case’s B-cells in the blood by flow cytometry (Figure 1D) but no consistent phenotypic differences between blood and lymph node were noted. Nine of 12 cases had flow cytometry and cytology performed concurrently on a lymph node aspirate. Cytologically, 5 cases were diagnosed as lymphoma of small-to-intermediate-sized lymphocytes (n = 1), intermediate lymphocytes (n = 1), or intermediate-to-large-sized lymphocytes (n = 3). One case was diagnosed as probable lymphoma, 2 as lymphoid hyperplasia, and 1 as normal.

3.3 | Breed differences

Clinical and clinicopathologic data were compared among 3 breed groups: small breeds with increased BCLL risk, Boxer dogs, and other breeds without increased risk of BCLL. No significant differences were found between small breeds with increased risk and the “other breeds” group, except for sex; therefore, small breed and “other breed” cases were combined into a non-Boxer group (n = 88). Comparing Boxer and non-Boxer cases, Boxers were significantly younger (median, 9.3 years) than non-Boxers (median, 10.6 years; P = .01) and Boxers had a higher presenting lymphocyte count (median, 72 700/μL) than did non-Boxers (27 000/μL; P < .001; Figure 2A). No difference was observed in the frequency of anemia, thrombocytopenia, hyperglobulinemia, lymphadenopathy, or splenic changes. By flow cytometry, Boxers had significantly larger B-cells compared to non-Boxers (P = .04; Figure 2B). B-cell CD21 and class II MHC expression was not significantly different. The median percentage of CD25-expressing B-cells was not significantly different, but a larger proportion of Boxers (20%) had very high CD25 expression (>98% CD25-expressing B-cells) compared to non-Boxers (4%; P = .04; Figure 2C).
3.4 | Clonality

Eighty-seven cases had PARR analysis, including on blood in 84 of 87 cases, splenic aspirate in 2 cases, and lymph node aspirate in 1 case. Eighty-five (98%) of 87 cases had clonal immunoglobulin rearrangements, supporting the diagnosis of B-cell neoplasia.

3.5 | Ki67 expression

Independent of the outcome study, the percentage of CD21+ B-cells expressing Ki67 (Ki67%) was determined by flow cytometry in controls (n = 12), BCLL cases (n = 202), and nodal B-cell lymphoma cases (B-cell size >500; n = 101) collected from 2017 to 2019. The BCLL cases included small breeds with increased risk of BCLL (n = 84), other small breeds (n = 32), non-Boxer medium-large breeds (n = 38), and Boxers (n = 48). A subset of those BCLL cases (n = 39) then was included in the outcome study. Low Ki67% expression was defined as <20% Ki67-expressing B-cells and high Ki67% as >40% Ki67-expressing B-cells.12 No significant difference in Ki67 expression was found between normal B-cells in the control blood (n = 5) and lymph node (n = 7) samples, and consequently these samples were combined for analysis. The median Ki67% in control B-cells was 8.5% and 11 of 12 control cases had low Ki67 (<20%) expression (Figure 3). Among non-Boxer BCLL breed groups, median Ki67% ranged from 14% to 16% and no significant differences were found among small breeds with increased BCLL risk, other small breeds, and non-Boxer medium-large breeds. Boxers with BCLL had significantly higher Ki67% (median, 42%) compared to non-Boxer BCLL cases (P < .0001). Nodal B-cell lymphoma cases (B-cell size >500) had significantly higher Ki67% (median, 64%) than all BCLL groups (P < .0001), and 87% of these nodal B-cell lymphoma cases had high Ki67 (>40%) expression. The percentage of high Ki67 (>40%) cases was significantly higher in Boxers with BCLL (58%) compared to non-Boxers with BCLL (27%; P < .0001), and the majority of non-Boxer BCLL cases (59%) had low Ki67 (<20%).

3.6 | Clinical outcome and survival analysis

The median survival time (MST) from flow cytometry diagnosis for all 121 outcome cases was 300 days (range, 1-1644 days). Boxers had significantly shorter survival (MST, 178 days) compared to non-Boxers (MST, 423 days; P < .0001; Figure 4A). No significant difference in
survival was found between small breed dogs and non-Boxer medium-large breed dogs (P = .46), and consequently all non-Boxer cases were combined for further analysis. Treatment across cases varied considerably (Table 1). Chemotherapeutics included chlorambucil, cyclophosphamide, vincristine, doxorubicin, mitoxantrone, L-asparaginase, mustargen, vinblastine, rabacfosadine, lomustine, melphalan, cytarabine, procarbazine, and dacarbazine. Across all dogs, first treatment pursued included no treatment for 30 dogs, corticosteroid only for 24 dogs, corticosteroid and chlorambucil for 41 dogs, and MTD chemotherapy for 24 dogs. For those dogs receiving chemotherapy at some point in their disease course, 48 dogs received a single chemotherapy protocol, 20 dogs received 2 chemotherapy protocols, and 11 received ≥3 chemotherapy protocols. For those dogs treated with corticosteroid alone as their first treatment, 9 of 24 had information available to retrospectively determine best response, and 1 dog had a CR, 4 dogs had PR, and 4 dogs had SDZ. For those dogs treated with corticosteroid and chlorambucil as their first treatment, 36 of 41 had a best response determined, and 39% had a CR, 39% had PR, and 22% had either SDZ or PD. For those dogs treated with MTD chemotherapy as their first treatment, 22 of 24 had a best response determined, and 41% had a CR, 55% had PR, and 1 dog had SDZ. It was not always clear why MTD chemotherapy was chosen for first treatment, but factors included marked lymphocytosis, recent rapid progression of lymphocytosis, and evidence of lymphoproliferative disease in solid tissues suggesting disseminated disease. Cases with peripheral lymphadenopathy (P = .001) or splenic abnormalities (P = .002) received MTD chemotherapy more frequently than did cases without abnormalities in those sites.

Among 67 cases that died or were euthanized, 30 (45%) cases had a BCLL-related death, 12 (18%) had a possible BCLL-related death, 3 (4%) had an unrelated death, 5 (7%) had a possible unrelated death, and in 17 (25%) cases the cause of death was unknown.

The Ki67 data were available for 39 cases with survival data, including 15 Boxers and 24 non-Boxers. High Ki67% (>40%) cases had significantly shorter survival (MST, 173 days; n = 28) compared with cases with <40% Ki67 (MST, undefined; n = 11; P = .03; Figure 4B). The 3 cases with <40% Ki67 expression that died included a non-Boxer with heartworm disease and bicavitary effusion that died at home and the only 2 Boxers in the <40% Ki67 group, which were both managed aggressively using multi-agent MTD protocols. When Boxers were omitted from Ki67 survival analysis, the results did not change, indicating that non-Boxers with high Ki67% also have poorer prognosis. Low-intermediate Ki67 cases (<40% Ki67) were managed with corticosteroids, chlorambucil or both (36%), or no treatment (36%), except for the 2 Boxers in the group (18%, MTD chemotherapy) and 1 non-Boxer that received lomustine for a lung tumor. Among high Ki67 cases (>40% Ki67), 46% received MTD chemotherapy, 43% received corticosteroids with or without chlorambucil, and 11% were untreated. Of those dogs with <40% Ki67 treated with chemotherapy (n = 6), only 2 dogs were treated with >1 protocol. Of those dogs with >40% Ki67 treated with chemotherapy (n = 16), 8 dogs were treated with >1 protocol.

Clinical and laboratory variables were assessed for association with survival in all cases, non-Boxer cases only, and Boxer cases only (Table 2). Among all cases, high presenting lymphocyte count, presence of clinical signs at diagnosis, and high CD25 expression were associated with significantly shorter survival. Presence of hyperglobulinemia was associated with significantly longer survival. Among non-Boxers only, lymphocyte count, clinical signs, and hyperglobulinemia were still similarly associated with survival, but CD25 expression was no longer associated with survival. Among Boxers only, presence of clinical signs and absence of splenomegaly or splenic masses were associated with significantly shorter survival. Across all cases, although the number was small, cases with lymphocytes described as intermediate-large in size by microscopy (n = 9) had significantly shorter survival than cases described as having lymphocytes that were small, small-intermediate, or intermediate in size. When cases with intermediate-sized lymphocytes were combined in the intermediate-large group, this finding was no longer significant. Six of the 9 cases with intermediate-large-sized lymphocytes were Boxers.
| Variable                        | Cutoff          | All cases (n = 121) | Non-Boxers (n = 88) | Boxers (n = 33) |
|--------------------------------|-----------------|---------------------|---------------------|-----------------|
|                                |                 | Number of cases | MST (days) | P  | Number of cases | MST (days) | P  | Number of cases | MST (days) | P  |
| Age                            | ≥10 years       | 70                | 364        | .46 | 57             | 423        | .38 | 13             | 181        | .25 |
|                                | <10 years       | 51                | 238        | .11 | 31             | 804        | .55 | 20             | 167        |     |
| Sex                            | Male            | 66                | 330        |     | 51             | 441        |     | 15             | 181        | .19 |
|                                | Female          | 55                | 250        |     | 37             | 377        |     | 18             | 154        |     |
| Lymphocyte count               | ≥60 000         | 45                | 173        |     | 25             | 173        |     | 20             | 178        | .70 |
|                                | <60 000         | 76                | 423        |     | 63             | 526        |     | 13             | 167        |     |
| Anemia                         | Present         | 50                | 288        | .48 | 35             | 314        | .48 | 15             | 250        | .14 |
|                                | Absent          | 71                | 300        | .59 | 53             | 423        |     | 18             | 149        |     |
| Thrombocytopenia               | Present         | 29                | 210        |     | 17             | 238        |     | 12             | 210        | .98 |
|                                | Absent          | 92                | 337        |     | 71             | 423        |     | 21             | 154        |     |
| B-cell size (flow cytometry)   | ≥0.50           | 63                | 289        |     | 40             | 423        | .91 | 23             | 178        | .66 |
|                                | <0.50           | 58                | 364        |     | 48             | 377        |     | 10             | 95         |     |
| Lymphocyte size (blood smear)  | Intermediate-large | 9            | 154        | .10 | 3              | 59         |     | 6              | 160        | .53 |
|                                | Small-intermediate | 98            | 346        |     | 75             | 427        |     | 23             | 181        |     |
| Hyperglobulinemia              | Present         | 22                | 804        | .02*| 16             | Undefined | .03*| 6              | 250        | .12 |
|                                | Absent          | 92                | 289        |     | 66             | 364        |     | 26             | 178        |     |
| Peripheral lymphadenopathy     | Present         | 62                | 245        | .09 | 41             | 300        | .09 | 21             | 178        | .92 |
|                                | Absent          | 55                | 423        |     | 44             | 642        |     | 11             | 167        |     |
| Visceral lymphadenopathy       | Present         | 31                | 250        | .15 | 20             | 292        | .09 | 11             | 250        | .78 |
|                                | Absent          | 36                | 337        |     | 27             | 526        |     | 9              | 202        |     |
| Splenic abnormalities          | Present         | 52                | 300        | .57 | 32             | 423        | .58 | 20             | 214        | .02*|
|                                | Absent          | 44                | 288        |     | 34             | 364        |     | 10             | 149        |     |
| Clinical signs                 | Present         | 45                | 149        | .003*| 31             | 200        | .03*| 14             | 68         | .005*|
|                                | Absent          | 74                | 346        |     | 55             | 427        |     | 19             | 210        |     |
| CD25 expression                | ≥64%            | 50                | 202        | .02*| 33             | 314        | .19 | 17             | 104        | .05 |
|                                | <64%            | 49                | 377        |     | 36             | 427        |     | 13             | 272        |     |
| CD21 expression (MFI)          | ≥48             | 50                | 364        | .12 | 36             | 526        | .04*| 14             | 167        | .44 |
|                                | <48             | 49                | 207        |     | 33             | 300        |     | 16             | 178        |     |
| Class II MHC expression (MFI)  | ≥158            | 50                | 250        | .57 | 37             | 364        | .58 | 13             | 167        | .51 |
|                                | <158            | 49                | 314        |     | 32             | 427        |     | 17             | 178        |     |
| Initial treatmenta             | MTD chemo       | 24                | 214        | .01*| 14             | 314        | .22 | 10             | 202        | .01*|
|                                | Steroid/chlorambucil | 41            | 441        |     | 31             | 559        |     | 10             | 330        |     |
|                                | Steroids only   | 24                | 125        |     | 15             | 245        |     | 9              | 68         |     |
|                                | None            | 30                | 423        |     | 27             | 427        |     | 3              | 210        |     |
| Maximum treatmentb             | MTD chemo       | 43                | 250        | .11 | 28             | 314        | .3  | 15             | 202        | .02*|
|                                | Steroid/chlorambucil | 36            | 526        |     | 29             | 526        |     | 7              | 167        |     |
|                                | Steroids only   | 20                | 178        |     | 13             | 364        |     | 7              | 69         |     |
|                                | None            | 21                | 293        |     | 18             | 423        |     | 3              | 210        |     |

Note: Undefined: median survival time not reached; *P-value < .05 was considered significant.
Abbreviations: MFI, median fluorescence intensity; MHC, major histocompatibility complex; MST, median survival time (days); MTD, maximum tolerated dose chemotherapy; n, number of cases.

aTreatment category represents the first protocol used.
bTreatment category represents the most intensive protocol pursued.
4 | DISCUSSION

Our study found that BCLL, defined by an expansion of small-sized CD21+ B-cells in the blood by flow cytometry, had variable clinical presentation and outcome. Cases had wide variability in overall survival times, and Ki67 expression was useful in identifying cases with a poorer prognosis. Additionally, Boxers with BCLL had significantly shorter overall survival.

The overall survival time for all 121 BCLL cases was 300 days (range, 1-1644 days); however, Boxers were intentionally over-represented in this population. When survival was assessed in non-Boxers, the MST of 423 days was similar to that previously reported for dogs with BCLL. A subset of cases had more indolent disease and were frequently asymptomatic. These cases were managed with corticosteroids, corticosteroids and chlorambucil, or no treatment, and had prolonged survival. Among non-Boxers, cases treated with corticosteroids and chlorambucil often had prolonged survival (MST, 526 days; range, 2-1478 days). However, a subset of BCLL cases had more aggressive disease and shorter overall survival. We aimed to find factors that would help identify these cases.

B-cell Ki67 expression, using cutoffs from a previous study in dogs, was variable in BCLL cases and associated with prognosis. Most non-Boxers had low-intermediate Ki67 expression (Ki67% <40%), but a subset of non-Boxers and most Boxers had high Ki67 expression (Ki67% >40%). Cases with high Ki67 expression, indicating increased cellular proliferation, had significantly shorter survival. Most nodal B-cell lymphoma cases (B-cell size >500) had Ki67% >40%. These nodal cases did not have histology, but most cases (87%) with B-cell lymphoma cases (B-cell size >500) had Ki67% >40%. These nodal cases had more aggressive disease and shorter overall survival. We hypothesized that Boxers with BCLL have more aggressive disease, because of preferential use of unmutated immunoglobulin heavy variable region genes in neoplastic B-cells, which is associated with poor prognosis in humans with CLL. Other factors, either in combination or regardless of immunoglobulin gene mutation status, could contribute to more aggressive disease in Boxers. In humans with CLL, there is a wide spectrum of identified mutations, and certain mutations, including SF3B1 and TP53 mutations, are associated with poorer prognosis. Boxers may have mutations associated with aggressive disease more frequently than other breeds. In our study, Boxers had significantly higher presenting lymphocyte counts, higher Ki67 expression, and shorter overall survival compared to non-Boxers. Additionally, we examined whether other medium-large breed dogs had poorer prognosis similar to Boxers, but these other breeds had similar Ki67 expression and survival as small breed dogs.

We hypothesize that BCLL in dogs can have different manifestations, as seen with CLL in humans, and Ki67 expression is useful in distinguishing subsets with different outcomes. These different subsets may have different small cell B-cell neoplasms, rather than different clinical manifestations of BCLL. Alternatively, all cases may have BCLL and the disease has a high degree of molecular, genetic, and clinical heterogeneity as seen in CLL in humans. A subset of human CLL patients has “accelerated CLL,” characterized by expanded proliferation centers in lymph nodes with a high proliferation rate and associated with aggressive disease. Gene expression profiling and identification of driver mutations would be useful in determining whether these canine BCLL cases represent a spectrum of a single disease or distinct diseases. Currently, antibodies are not available to differentiate these BCLL subsets by routine immunophenotyping, because our canine B-cell antibodies are limited and class II MHC and CD21 expression was variable across subsets and substantial overlap in CD25 expression was found among groups.

In addition to Ki67 expression and breed, we found that lymphocyte count, presence of clinical signs, and hyperglobulinemia were associated with prognosis. A high presenting lymphocyte count (>60 000/μL) was associated with shorter survival in non-Boxer BCLL cases. Lymphocyte count was not prognostic in 2 prior studies of BCLL in dogs. These studies may not have detected a difference because of smaller sample sizes (n = 17 and n = 21), or because they assessed association with survival using a different lymphocyte cutoff (30 000/μL) or lymphocyte count as a continuous variable. In our study, lymphocyte count was not prognostic when using the median lymphocyte count of the study population as a cutoff (40 000/μL), but was prognostic when the cutoff was increased to 60 000/μL. Those BCLL cases presenting with clinical signs had significantly shorter survival, which is an important prognostic factor in other types of lymphoma in dogs. Hyperglobulinemia affected 19% of canine BCLL cases at diagnosis and was associated with longer survival. In humans with CLL, paraproteins are associated with poor prognosis. It was surprising that canine BCLL cases with hyperglobulinemia had prolonged survival, but only 8 cases had serum protein electrophoresis and it is unknown whether the hyperglobulinemia was attributed to a paraprotein in all cases. If paraprotein cases have prolonged survival, perhaps those cases have different signals driving B-cell stimulation or the neoplastic B-cells are more differentiated, affecting the clinical disease course. High CD25 expression was associated with shorter survival across all cases, but not when assessed in non-Boxers only. Increased CD25 expression is associated with poor prognosis in dogs with diffuse large B-cell lymphoma, but more work is needed to fully elucidate its prognostic relevance in dogs with BCLL. Age was not prognostic in our study as it was in a prior study. Most cases in our study were middle-aged to older (only 7/121 [6%] were <6 years old), and perhaps too few young cases were available to detect a difference in survival.

We included all cases with a flow cytometry diagnosis of BCLL, regardless of tissue involvement. In humans, CLL commonly affects secondary lymphoid tissues and SLL, which is defined by lymphadenopathy, splenomegaly, or both, is considered the same neoplasm as CLL without a leukemic component. Therefore, we did not want to exclude canine BCLL cases with secondary lymphoid organ enlargement and found that lymphadenopathy and splenic changes were common. These cases more often received MTD chemotherapy.
All 12 cases with flow cytometry performed on a lymph node aspirate had a marked expansion of small-sized B-cells, consistent with neoplasia. These cases had a wide range of cytology diagnoses, emphasizing the difficulty in diagnosing small cell neoplasms by cytology alone. In the peripheral blood, lymphocyte cell size also was variable across pathology reports. It was not unusual for cases to be described as having intermediate-sized lymphocytes; these cases had small B-cell size by flow cytometry and had the same prognosis as cases described as small-sized. These findings suggest that BCLL tumors may have intermediate-sized lymphocytes described using lymph node or blood microscopy and this morphology does not necessarily indicate a different tumor or prognosis. Nine cases had intermediate to large-sized lymphocytes in the blood by microscopy and these cases did have a poorer prognosis. These cases may represent more aggressive BCLL disease or a different B-cell neoplasm. Nuclear descriptions were variable or lacking in these cases, making it difficult to fully characterize the cells. Future studies that objectively characterize morphology on fresh blood films are needed to evaluate the prognostic utility of morphologic features. In humans, CLL may have admixed larger cells and up to 55% prolymphocytes, and cases with increased prolymphocytes have poorer prognosis.\(^{35}\) A previous study of CLL in dogs found that prolymphocytes were not prognostic, but only 1 of 17 BCLL cases had >10% prolymphocytes.\(^{3} \)

Limitations of our study included its retrospective study design, incomplete staging for some cases, variable treatment protocols, and lack of necropsies. Additionally, by including cases with tissue involvement, atypical cellular morphology or both, we may have included cases with a different small cell B-cell neoplasm. For example, 27% of cases with a histologic diagnosis of diffuse small B-cell lymphoma had lymphocytosis, suggesting some cases may present similarly to BCLL.\(^{36}\) However, we currently cannot differentiate subtypes of small cell B-cell neoplasms by immunophenotyping, and therefore wanted to include any cases with a diagnosis of BCLL by routine flow cytometry. Additionally, not all cases with lymphadenopathy had cytology, and few had nodal histology or flow cytometry. Therefore, we cannot confirm whether cases developed diffuse large B-cell lymphoma or another aggressive lymphoma (Richter syndrome). Richter syndrome is reported in 2% to 10% of human CLL cases and 11% of canine BCLL cases.\(^{2,37}\)

Thus, in the more aggressive cases in our study, we could not determine whether cases had Richter transformation or progressive BCLL. In conclusion, BCLL in dogs, as defined by flow cytometry, has a variable clinical course. Future work to evaluate differences in gene expression and mutations among subsets with different clinical behavior will be particularly important.

ACKNOWLEDGMENT
Funding provided by Morris Animal Foundation, D18CA-413. The authors thank the veterinarians and clients who have provided valuable information and samples for these cases.

CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.

REFERENCES
1. Bromberek JL, Rout ED, Agnew MR, Yoshimoto J, Morley PS, Avery AC. Breed distribution and clinical characteristics of B cell chronic lymphocytic leukemia in dogs. J Vet Intern Med. 2016;30(1):215-222. https://doi.org/10.1111/jvim.13814.
2. Comazzi S, Martini V, Riondato F, et al. Chronic lymphocytic leukemia transformation into high-grade lymphoma: a description of Richter’s syndrome in eight dogs. Vet Comp Oncol. 2017;15(2):366-373. https://doi.org/10.1111/vco.12172.
3. Comazzi S, Gelain ME, Martini V, et al. Immunophenotype predicts survival time in dogs with chronic lymphocytic leukemia. J Vet Intern Med. 2011;25(1):100-106. https://doi.org/10.1111/j.1939-1676.2010.0640.x.
4. Workman HC, Vernau W. Chronic lymphocytic leukemia in dogs and cats: the veterinary perspective. Vet Clin North Am – Small Anim Pract. 2003;33(6):1379-1399. https://doi.org/10.1016/S0195-5616(03)00120-7.
5. Vernau W, Moore PF. An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol. 1999;69:145-164. https://doi.org/10.1016/S0165-2427(99)00051-3.
6. Tasca S, Carli E, Caldin M, Menegazzo L, Furlanello T, Gallego LS. Hematologic abnormalities and flow cytometric immunophenotyping results in dogs with hematopoietic neoplasia: 210 cases (2002-2006). Vet Clin Pathol. 2009;38(1):2-12. https://doi.org/10.1111/j.1939-165X.2008.00099.x.
7. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946-965. https://doi.org/10.1002/ajh.24826.
8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood. 2008;111(12):5446-5457. https://doi.org/10.1182/blood-2007-06-093906.
9. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-then and now. Am J Hematol. 2016;91(3):330-340. https://doi.org/10.1002/ajh.24282.
10. The International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. https://doi.org/10.1016/S1470-2045(16)30029-8.
11. Williams MJ, Avery AC, Lana SE, Hillers KR, Bachand AM, Avery PR. Canine lymphoproliferative disease characterized by lymphocytosis: Immunophenotypic markers of prognosis. J Vet Intern Med. 2008;22(3):596-601. https://doi.org/10.1111/j.1939-1676.2008.0041.x.
12. Poggi A, Miniscalco B, Morello E, et al. Prognostic significance of Ki-67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma. Vet Comp Oncol. 2017;15(2):431-440. https://doi.org/10.1111/vco.12184.
13. Giné E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic
lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526-1533. https://doi.org/10.3324/haematol.2010.022777.

14. Morabito F, Cutrona G, Gentile M, et al. More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. Leuk. Res. 2010;34(12):326-328. https://doi.org/10.1016/j.leukres.2010.07.036.

15. Bruey JM, Kantarjian H, Ma W, et al. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk. Res. 2010;34(10):1320-1324. https://doi.org/10.1016/j.leukres.2010.03.010.

16. Rout ED, Burnett RC, Labadie JD, Yoshimoto JA, Avery AC. Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia. PLoS One. 2016;11(1):1-16. https://doi.org/10.1371/journal.pone.0191205.

17. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.

18. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.

19. Rout ED, Moore AR, Burnett RC, et al. Polyclonal B-cell lymphocytosis in English bulldogs. J Vet Intern Med. 2020;34(6):2622-2635. https://doi.org/10.1111/jvim.15913.

20. Wolf-Ringwall A, Lopez L, Elmslie R, et al. Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. Vet Comp Oncol. 2020;18(3):342-352. https://doi.org/10.1111/vco.12553.

21. Seelig DM, Avery P, Webb T, et al. Canine t-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics. J Vet Intern Med. 2014;28(3):878-886. https://doi.org/10.1111/jvim.12343.

22. Colopy LJ, Shiu KB, Snyder LA, Avery AC, Rout ED, Moore AR. Immunoglobulin G4-related disease in a dog. J Vet Intern Med. 2019;33(6):2732-2738. https://doi.org/10.1111/jvim.15624.

23. Gong JZ, Williams DC, Liu K, Jones C. Fine-needle aspiration of mediastinal masses in cats: a retrospective study. Front Vet Sci. 2020;7(August):1-8. https://doi.org/10.3389/fvets.2020.00444.

24. Bernardi S, Martini V, Perfetto S, Cozzi M, Comazzi S. Flow cytometric analysis of mediastinal masses in cats: a retrospective study. Front Vet Sci. 2020;7(August):1-8. https://doi.org/10.3389/fvets.2020.00444.

25. Gellain ME, Mazzioli M, Riondato F, Marconato L, Comazzi S. Aberrant phenotypes and quantitativ expression in different subtypes of canine lymphoma by flow cytometry. Vet Immunol Immunopathol. 2008;121(3-4):179-188. https://doi.org/10.1016/j.vetimm.2007.09.018.

26. Balakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336. https://doi.org/10.1038/leu.2014.196.

27. Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018;8(10):01312. 93https://doi.org/10.1038/s41408-018-0131-2.

28. Comazzi S, Gellain ME. Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. Vet J. 2011;188(2):149-155. https://doi.org/10.1016/j.tvjl.2010.03.011.

29. Keller ET, MacEwen EG, Rosethal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med. 1993;7(5):289-295. https://doi.org/10.1111/j.1939-1676.1993.tb01021.x.

30. Jägielski D, Lechowski R, Hoffmann-Jägielska M, Winiarczyk S. A prospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med Ser A Physiol Pathol Clin Med. 2002;49(8):419-424. https://doi.org/10.1046/j.1439-0442.2002.00458.x.

31. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011;118(10):2821-2826. https://doi.org/10.1182/blood-2011-04-349134.

32. Xu W, Wang YH, Fan L, et al. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. Leuk Res. 2011;35(8):1060-1065. https://doi.org/10.1016/j.leukres.2010.12.005.

33. Rizzo D, Chauzeix J, Timoreau F, et al. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenic events. Leukemia. 2015;29(2):337-345. https://doi.org/10.1038/leu.2014.198.

34. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.

35. Oscier D, Else M, Matutes E, Morilla R, Streford JC, Catovsky D. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol. 2016;174(5):767-775. https://doi.org/10.1111/bjh.14132.

36. Hughes KL, Ehrhart EJ, Rout ED, et al. Diffuse small B-cell lymphoma: a high-grade malignancy. Vet Pathol. 2021;58:030098582098522.

37. Jamrozik K, Tadmor T, Robak T, Pollack A, Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015;56(7):1949-1958. https://doi.org/10.3109/10428194.2014.979411.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.